Investors

Intervacc have now come to a phase where several challenges in clinical trials and manufacturing have been overcome. We see that our main product, Strangvac®, has satisfied expected results in efficacy studies and we have seen that manufacturing of components in the vaccine can be made with a cost effective process. In addition to the remaining steps to launch Strangvac®, we will strengthen the company´s business idea to become a leading company within animal health, which can provide the market with veterinary vaccines and pharmaceuticals.

This means that the company now takes a clear step towards becoming a company with several products rather than only one. We will thus spend further force on the development of a vaccine against a streptococcal infection in piglets. For our subsidiary Nordvacc it means that new distribution agreements recently have been signed and further discussions are presently going on.

Jan-Ingmar Flock,
CEO

Investor presentation August 27, 2018

CEO Jan-Ingmar Flock presents Intervacc and the development of a new generation of vaccines within animal health. Strangvac® – our vaccine against equine strangles is first and the development of two other vaccines INV274 and INV412 continues with new funding from Eurostars-2/Horizon 2020 and Vinnova.

Here you can see the recorded and transcribed presentation which is about 23 minutes including the following Q&A.